OTHER SYNTHETICS BILL STATUS REPORT CARRYOVER, 2012, AND SPECIAL SESSIONS

2012 Research is current as of March 16, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

State Colorado D.C. Florida

Bill No. S.B. 116 L.B. 645 H.B. 1175 Adds MPHP

Brief Description

Adds 2C-T-7, 5-MeO-DiPT adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4, 2CT-7, 5-MeO-DiPT, 5-MeO-DMT, chlorophenylpiperazine, DiPT, DOC, DOI, DPT, fluorophenylpiperazine, methyltryptamine, MPHP, TFMPP adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4, 2CT-7, 5-MeO-DiPT, 5-MeO-DMT, chlorophenylpiperazine, DiPT, DOC, DOI, DPT, fluorophenylpiperazine, methyltryptamine, MPHP, TFMPP Adds fluorophenylpiperazine

Date of Last Action Third reading passed 3/16/2012 and reconsidered Scheduled for 1/13/2012 hearing on 3/16 Signed by officers 3/16/2012 and presented to Governor

Status

Florida

S.B. 1502

Substituted by H.B. 1175; laid on the table

3/6/2012

Georgia

S.B. 370

Hawaii Hawaii Idaho Indiana Indiana

H.B. 2600 S.B. 2862 H.B. 502 H.B. 1196 S.B. 234

Adds 5-MeO-DMT Adds 5-MeO-DiPT, 5-MeO-DMT Adds 5-MeO-DMT Adds 6-APB, methoxetamine Adds 6-APB, methoxetamine

Iowa Iowa Iowa Kentucky Kentucky

H.F. 2398 H.S.B. 609 S.S.B. 3104 S.B. 188 H.B. 481

adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4 adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4 adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4 adds TFMPP adds TFMPP

Passed Senate; in House second readers Public hearing scheduled for 3/21 Referred to committee To third reading Signed by Governor Senate dissented from House amendments; conferees and advisors appointed Passed House; in Senate committee Voted public safety introduced In Senate committee Passed with committee substitute; received in Senate In Senate committee In House committee

2/24/2012

3/16/2012 1/25/2012 3/16/2012 3/15/2012 3/8/2012

3/15/2012 2/23/2012 1/30/2012 3/5/2012 3/14/2012

Kentucky Kentucky

S.B. 173 H.B. 198

adds TFMPP adds TFMPP

2/28/2012 1/5/2012

2012 Research is current as of March 16, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Kentucky Kentucky Louisiana

H.B. 176 H.B. 185 S.B. 195

adds TFMPP adds TFMPP Adds phenazepam

Minnesota

S.F. 2319

Minnesota

H.F. 2508

Mississippi Mississippi New York

H.B. 730 S.B. 2463 S.B. 5181

adds 2C-C, 2C-T-4, 2C-T-7, 4-HO-DiPT, 5IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeOMiPT, 6-APB, DiPT, DOC, DOI, methoxetamine adds 2C-C, 2C-T-4, 2C-T-7, 4-HO-DiPT, 5IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeOMiPT, 6-APB, DiPT, DOC, DOI, methoxetamine Adds 5-MeO-DMT Adds 5-MeO-DMT Adds 2C-E

In House committee In House committee Read second time and referred to committee Committee report to pass as amended; second reading

1/4/2012 1/4/2012 3/12/2012

3/19/2012

Committee report to 3/5/2012 pass and re-refer to second committee In Senate committee Died in committee Recommit to committee; enacting clause stricken Passed Assembly; referred to Senate committee Referred to committee Referred to committee Second reading; referred to committee Signed by Governor Passed Senate; held on House desk Placed on subcommittee calendar for 3/21 Passed both houses; signed by Speaker and President Passed both houses; signed by Speaker and President Left in courts of justice Incorporated into 3/15/2012 3/6/2012 1/9/2012

New York

A.B. 7917

Adds 5-MeO-DMT

2/15/2012

New York New York Oklahoma

S.B. 4460 A.B. 5008 H.B. 2942

Adds 5-MeO-DMT Adds TFMPP Adds DOC

1/4/2012 1/4/2012 3/15/2012

South Dakota Tennessee Tennessee

S.B. 23 S.B. 2230 H.B. 2368

adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4 adds 5-MeO-DMT adds 5-MeO-DMT

2/24/2012 2/16/2012 3/14/2012

Virginia

S.B. 273

adds 2C-E, 2C-I, 5-MeO-DALT

3/9/2012

Virginia

H.B. 508

adds 2C-E, 2C-I, 5-MeO-DALT

3/8/2012

Virginia Virginia

H.B. 986 S.B. 223

adds 2C-E, 2C-I, 5-MeO-DALT adds 2C-E, 2C-I, 5-MeO-DALT

2/14/2012 1/23/2012

2012 Research is current as of March 16, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

West Virginia United States United States

S.B. 667 HR 1254

adds 2C-T-7, 5-MeO-DiPT, 5-MeO-DMT adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4

S 839

adds 2C-C, 2C-E, 2C-I, 2C-T-2, 2C-T-4

S.B. 273 Referred to committee Passed House; referred to Senate committee Placed on Senate legislative calendar

2/22/2012 12/8/2011

7/28/2011

2012 Research is current as of March 16, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.